Compare Amgen, Inc. (AMGN) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Ecopetrol SA — how do they compare? Amgen, Inc. trades at $357.4 (market cap $196.12B), while Ecopetrol SA trades at $15.77 (market cap $29.34B). The key difference: Amgen, Inc. is far larger — about 6.7× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (4.17%). Which is the better fit depends on your goals.
| AMGN | EC | |
|---|---|---|
Market Cap | $196.12B | $29.34B |
Sector | Health | Energy |
52-Week High | $388.16 | $16.58 |
52-Week Low | $271.18 | $8.29 |
Enterprise Value | $241.41B | $57.13B |
Dividend Yield | 2.77% | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Ecopetrol (EC) trades at $15.58, up 1.23% with bullish technical signals from moving averages. The stock shows mixed fundamentals with declining revenue from $159.6B in 2022 to $119.7B in 2025, though maintains stable 8.76% net margins. Recent corporate developments include a $0.66 dividend payment and S&P credit rating affirmation at BB- with stable outlook as of June 17, 2026.
EC presents a cautious opportunity with attractive valuation multiples (P/E 11.1, P/S 0.97) but faces revenue headwinds. Analyst consensus is mixed with 27% buy ratings and $14.63 target below current price. Key risks include energy price volatility and execution challenges amid declining cash flows from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
